Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR PHARM-B) disclosed a voluntary plan to repurchase its H shares on the open market, leveraging the general mandate granted at the 25 August 2025 annual general meeting. The mandate authorises the board to buy back a maximum amount equivalent to 10% of the company’s H shares then in issue.

The board resolution approved on 6 May 2026 sets the groundwork for periodic repurchases, contingent upon: 1. Regulatory clearance for foreign-exchange remittance in mainland China, and 2. Separate shareholder approval for amendments to the company’s Articles of Association covering share buy-backs.

Management stated that available financial resources are sufficient to undertake the programme without compromising balance-sheet strength. The initiative is positioned as a signal of confidence in the company’s outlook and a means of enhancing shareholder value.

Execution timing, volume and pricing will depend on prevailing market conditions and remain at the board’s sole discretion; the company cautioned that repurchases may vary or not occur at all. Investors are advised to exercise prudence when trading the shares.